Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

Marre, M; Shaw, J; Brändle, M; Bebakar, WM; Kamaruddin, NA; Strand, J; Zdravkovic, M; Le, Thi TD; Colagiuri, S; De Loredo, L; Waitman, J; Litwak, L; Rodriguez, M; Vines, G; Maffei, L; Issa, C; Lowy, A; Bartley, P; Kamp, M; Shaw, J; ... (2009). Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). Diabetic medicine, 2009(26(3)), pp. 268-78. Chichester: Wiley 10.1111/j.1464-5491.2009.02666.x

Full text not available from this repository.

Item Type:	Journal Article (Original Article)
Division/Institute:	04 Faculty of Medicine > Department of Gynaecology, Paediatrics and Endocrinology (DFKE) > Clinic of Endocrinology, Diabetology and Clinical Nutrition
UniBE Contributor:	Christ, Emanuel
ISSN:	0742-3071
Publisher:	Wiley
Language:	English
Submitter:	Factscience Import
Date Deposited:	04 Oct 2013 15:14
Last Modified:	05 Dec 2022 14:22
Publisher DOI:	10.1111/j.1464-5491.2009.02666.x
Web of Science ID:	000264163800011
URI:	https://boris.unibe.ch/id/eprint/32624 (FactScience: 197861)